Radoptics was originally established with the goal being clinical translation of the pioneering technologies developed at Dr. Bahman Anvariâs laboratory in the Department of Bioengineering, UC Riverside involving cell-based phototheranostics. The firm is structured around commercializing these cutting-edge technologies towards applications in intraoperative or endoscopic imaging and phototherapeutics. The technology involves the engineering and fabrication of erythrocyte-derived vesicles with tunable diameters and containing appropriate formulations of probes for image-guided therapeutics of solid cancers and vascular diseases on an individual patient basis. ⢠RBC-based nano and micro particles ⢠Ease of custom targeting various cancer biomarkers ⢠Platform for combined chemo- and photo-therapeutics. In relation to cancer imaging and therapy, Radoptics technologies can provide a capability for image-guided surgical removal of small tumor nodules that are not otherwise visually detectable during surgery, or pre-operatively by current imaging methods, and mediate destruction of tumor cells through a combination of chemotherapy and pulsed near infrared thermal t
